RBC
ALXN

Roble Belko & Company’s Alexion Pharmaceuticals ALXN Stock Holding History

Roble Belko & Company’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-61
Closed -$7K – 359
2017
Q1 		$7K Hold
61
– – ﹤0.01% 243
2016
Q4 		$7K Buy
+61
New +$7.46K ﹤0.01% 254

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Roble Belko & Company's ALXN Position: Q2 2017 in Review

Roble Belko & Company sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 61 shares — an estimated $7K sold.

Roble Belko & Company first reported a position in ALXN in Q4 2016 and held it in 2 quarters. The position peaked at $7K in Q1 2017. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • Roble Belko & Company reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Roble Belko & Company sold 61 Alexion Pharmaceuticals shares in Q2 2017, an estimated $7K.
  • Roble Belko & Company first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Roble Belko & Company's Alexion Pharmaceuticals position peaked at $7K in Q1 2017.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Roble Belko & Company's 13F filing for Q2 2017, filed 11 Aug 2017.